v3.25.4
OTHER (INCOME)/EXPENSE, NET - Schedule of Other Income (Expense) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Alliance Statement [Line Items]      
Interest expense $ 1,891 $ 1,947 $ 1,166
Royalty income - divestitures (Note 4) (1,129) (1,104) (862)
Royalty and licensing income (Note 4) (1,093) (736) (1,488)
Investment income (586) (478) (449)
Provision for restructuring (Note 6) 563 635 365
Litigation and other settlements(a) 434 84 (390)
Loss on debt redemption (Note 10) 356 0 0
Contingent consideration (Note 9) 351 0 0
Equity investment (gains)/losses, net (Note 9) (280) (16) 160
Integration expenses (Note 6) 147 284 242
Acquisition expense 9 50 32
Other 11 227 66
Other (income)/expense, net $ 674 $ 893 (1,158)
Defined Benefit Plan Net Periodic Benefit Cost Credit Settlement Gain Loss Statement Of Income Or Comprehensive Income Extensible List Not Disclosed Flag   pension settlement charges  
Pension settlement charges   $ 119  
AstraZeneca      
Alliance Statement [Line Items]      
Income related to collaboration termination     384
Nimbus Therapeutics      
Alliance Statement [Line Items]      
Income related to collaboration termination     400
BeiGene      
Alliance Statement [Line Items]      
Income related to collaboration termination     $ 322